Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

REGN 3048

Drug Profile

REGN 3048

Alternative Names: REGN3048

Latest Information Update: 03 May 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Regeneron Pharmaceuticals
  • Developer National Institute of Allergy and Infectious Diseases; Regeneron Pharmaceuticals
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Viral protein inhibitors; Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Middle East respiratory syndrome coronavirus

Most Recent Events

  • 12 Feb 2018 Phase-I clinical trials in Middle East respiratory syndrome coronavirus (In volunteers) in USA (IV) (NCT03301090) (Regeneron pipeline, May 2018)
  • 02 Oct 2017 Regeneron Pharmaceuticals plans a NIH-sponsored phase I trial for Middle East respiratory syndrome coronavirus by the end of 2017
  • 22 Aug 2016 Regeneron Pharmaceuticals enters into a collaboration agreement with Sanofi to develop human monoclonal antibodies for Middle East respiratory syndrome coronavirus before August 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top